Abstract Mounting evidence supports that cadmium, a toxic metal found in tobacco, air and food, is a cardiovascular risk factor. Our objective was to conduct a systematic review of epidemiologic studies evaluating the association between cadmium exposure and cardiovascular disease. Twelve studies were identified. Overall, the pooled relative risks (95 % confidence interval) for cardiovascular disease, coronary heart disease, stroke, and peripheral arterial disease were: 1.36 (95 % CI: 1.11, 1.66), 1.30 (95 % CI: 1.12, 1.52), 1.18 (95 % CI: 0.86, 1.59), and 1.49 (95 % CI: 1.15, 1.92), respectively. The pooled relative risks for cardiovascular disease in men, women and never smokers were 1.29 (1.12, 1.48), 1.20 (0.92, 1.56) and 1.27 (0.97, 1.67), respectively. Together with experimental evidence, our review supports the association between cadmium exposure and cardiovascular disease, especially for coronary heart disease. The number of studies with stroke, heart failure (HF) and peripheral arterial disease (PAD) endpoints was small. More studies, especially studies evaluating incident endpoints, are needed.
Introduction
Cadmium is a non-essential carcinogenic metal widely distributed in the environment [1, 2] . A by-product of mining, smelting and refining zinc, lead and copper ores, cadmium production and use has substantially increased, particularly in nickel-cadmium batteries, fertilizers, coatings and plastic stabilizers [1, 3] . The impact of cadmium-containing products (nickel-cadmium batteries, electronic devices, jewelry and toys) [3] and cadmium-containing fertilizers on human exposure through soil and diet [4, 5] is a major concern. Indeed, leafy and root vegetables and grains bioconcentrate cadmium from the soil, especially in acidic soils, resulting in a major exposure pathway through the diet and smoking [4, 6, 7] . Ambient air and dust can also contribute to cadmium exposure, particularly in urban areas, in the vicinity of occupational and industrial sources [8, 9] and in certain occupational groups (metal and mining industry, transportation and repairing services) [10] .
Experimental evidence [11] suggests that cadmium could contribute to the initiation of atherosclerosis and promote progression. In vitro, cadmium induces endothelial dysfunction, and in vivo, it accelerates atherosclerotic plaque formation [11] . Several mechanisms have been suggested to explain the role of cadmium in promoting atherosclerosis. Cadmium may increase reactive oxygen species formation [12] and interfere with anti-oxidative stress responses by binding metallothionein [13] , a low molecular weight protein that regulates zinc homeostasis and acts as a free radical scavenger [12, 14] . Cadmium may also contribute to atherosclerosis by increasing blood pressure [15] [16] [17] , or through kidney damage [18, 19] , cadmium-related estrogenic activity [20] [21] [22] , or epigenetic changes [23] . The relevance of these mechanisms to cadmium-induced atherogenesis is uncertain.
In epidemiologic studies, cadmium concentrations in blood and urine are established biomarkers of cadmium exposure and internal dose [1, 9, 24] . Both biomarkers reflect cumulative exposure, although blood cadmium also reflects short-term fluctuations in exposure [1, 9, 24] . Prospective studies [25] [26] [27] 28 ••, 29••] investigating the association of cadmium concentrations with cardiovascular outcomes have mostly supported an association with cardiovascular risk, but the evidence has not been appraised systematically. Our objective was to systematically review and synthesize results from epidemiologic studies on the association between cadmium biomarkers and cardiovascular disease.
Methods

Search Strategy, Study Selection and Data Abstraction
We searched PubMed for relevant published studies through April 15, 2013 (Fig. 1) . We included all articles assessing cadmium exposure using biomarkers. We limited the search to clinical cardiovascular disease (CVD), defined a priori as coronary heart disease (CHD) (including myocardial infarction and ischemic heart disease), stroke (cerebrovascular disease, ischemic and hemorrhagic stroke) and peripheral arterial disease (PAD) (lower-extremity peripheral arterial disease, diseases of the peripheral arteries, and blackfoot disease), as well as overall CVD. The search had no language restrictions. We also included three relevant studies published after April 15, 2013 
Two investigators (M.T-P and M.R.J.) independently reviewed each of 874 papers and selected 37 papers applying the following study exclusion criteria ( Fig. 1 ): a) No original research (i.e. reviews, editorials, non-research letters); b) No human study; c) Case report or case series; d) No clinical cardiovascular outcomes (e.g. subclinical atherosclerosis); e) No cadmium exposure levels from biological tissues (e.g. environmental measures such as water or air, or distance from a cadmium source). Age, sex and smoking are major determinants of cadmium levels in the human body and major risk factors for cardiovascular disease. We thus excluded 20 studies not adjusting for age, sex or smoking [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . One large prospective study from Japan [52••] did not adjust for smoking. Smoking was very rare among women in this rural population [52••] , and we included the results for women as part of our systematic review and meta-analysis. For studies analyzing the same cardiovascular endpoints in the same study population, we selected the most recent publication or the publication with the largest sample size, resulting in the exclusion of five papers [25, [53] [54] [55] [56] and leaving 12 studies. Any discrepancies were resolved by consensus. A native speaker reviewed the fulltext of any non-English article that could not be included or excluded based on the initial abstract review. After retrieval of articles from the search, the reference lists of selected articles were checked for other potentially relevant articles, identifying no additional studies. We assessed study quality according to the criteria adapted from Longnecker and colleagues [57] Measures of association for a change in cadmium levels and their standard errors or 95 % confidence intervals (CI) were abstracted or derived using the data reported in the publication. For some studies that reported only the association for cadmium categories, we reported the estimated relative risk comparing the highest to the lowest categories [27, 30••, 52••, 58] . Results presented separately for males and females were combined within each study. Pooled relative risk estimates for CVD were calculated overall, and in men, women and never smokers from individual studies, using an inverse variance weighted random effects model. For descriptive purposes, we also estimated pooled relative risk for specific cardiovascular outcomes (coronary heart disease, stroke or peripheral arterial disease). Two study populations had information on both prevalence and mortality for cardiovascular disease and coronary heart disease [27, 28••, 58, 59, 60•] . We considered prevalence and mortality endpoints as qualitatively different endpoints and pooled them together in the main analyses. As a sensitivity analysis, we conducted the pooling after excluding prevalent cardiovascular endpoints in the aforementioned study populations (Online Resource 2). We evaluated heterogeneity between studies using the I 2 statistic, which describes the total variability across all studies due to heterogeneity [61] . Additionally, we tested for influential studies by omitting each study sequentially and assessed publication bias using funnel plots.
Results
Twelve studies met the primary and secondary exclusion criteria (Table 1 ; Fig. 1 Cross-sectional studies were based on prevalent cases and interviewers were blinded to exposure status. All cross-sectional studies reported an overall response rate of at least 70 % [64, 65] .
In prospective studies, cadmium was associated with CVD, CHD, stroke, HF and PAD in five (out of five, although the association in one study [26] was borderline statistically significant), two (out of four), two (out of three), one (out of one) and two (out of two) studies, respectively (Table 1 ). In crosssectional studies, cadmium was associated with CVD, CHD, stroke, HF and PAD in one (out of one), three (out of three), one (out of one), one (out of one) and one (out of one) studies, respectively ( Table 1) .
The pooled relative risk estimates comparing the highest to lowest cadmium exposure categories were 1.36 for CVD (95 CI, confidence interval, CVD, cardiovascular disease; CHD, coronary heart disease; PAD, peripheral arterial disease; RR, relative risk; NA, not available a For the overall we kept only one result for one specimen (urine preferred) but for the individual biomarker pooling we used the biomarker if available even if not included in the overall ranged from 1.21 [27] (Fig. 2) . In sensitivity analysis excluding prevalent CVD and CHD in NHANES populations with available CVD and CHD endpoints, the results were similar (Online Resource 2). The evaluation of publication bias was limited due to the small number of studies.
Discussion
Cadmium is an established carcinogen [2] , also known to cause respiratory, kidney and bone disease in highly polluted environments, including occupational settings [1, 9] . The findings from this systematic review support that cadmium is associated with cardiovascular disease in general populations exposed to low-to-moderate levels of cadmium exposure. The association was similar for both men and women, although it was not significant for women. The association for never smokers was suggestive but not significant. The number of studies with stroke, HF and PAD endpoints was small and more studies are needed, especially prospective studies ascertaining incident outcomes.
Cadmium Metabolism and Biomarkers
Cadmium is incorporated into the body through the respiratory and digestive tracts using transporters for essential divalent metals (e.g., zinc, iron, manganese, and calcium), such as the zinc transporter Zrt, Irt-like member 8 protein (ZIP-8) and divalent metal transporter (DMT-1) [9, 66] . In blood, cadmium is transported bound mainly to metallothioneins (MTs), which are proteins with a high heavy-metal-binding capacity [13] that have been associated with protection against toxic metals [13] . In the kidney, filtered cadmium-MT compounds are transported into the proximal tubule cells, where they bioaccumulate [9] . Urine cadmium reflects kidney cadmium [67] and, consequently, has been considered a biomarker of cumulative body burden. Recent studies, however, have shown that urine cadmium levels are also related to physiological changes [68] , and there are some concerns about the usefulness of urine cadmium as a biomarker of long-term cadmium exposure in populations exposed to low-moderate cadmium levels [69] . Blood cadmium is more dependent on daily fluctuations in exposure and has been considered a marker of ongoing exposure. However, in cadmium-exposed workers, the half-life of blood cadmium showed a fast component (3-4 months) and a slow component (10 years) supporting the hypothesis that, after long-term exposure, blood cadmium levels may also reflect the body's burden of cadmium [24] . In our meta-analysis, we separately combined studies using blood and urine cadmium biomarkers, with similar results. Altogether, these results support that both biomarkers can reflect cumulative exposure.
Cadmium and Clinical CVD Endpoints
The findings from our meta-analysis indicate statistically significantly higher risk with higher cadmium levels for all Fig. 2 Relative risks for cardiovascular disease endpoints per change in cadmium levels. The area of each black square (individual study) is proportional to the inverse of the variance of the estimated log relative risk. Horizontal lines represent 95 % confidence intervals. CI, confidence interval; CVD, cardiovascular; CHD, coronary heart disease; HF, heart failure; PAD, peripheral arterial disease; RR, relative risk clinical cardiovascular endpoints, except for stroke. Overall, this is supportive evidence that cadmium is a cardiovascular risk factor. Half of the studies included in the meta-analysis were conducted in the National Health and Nutrition Examination Survey (NHANES). NHANES is a major program of the U.S. National Center for Health Statistics. A complex, multistage, probability sampling design was used to select participants that are representative of the civilian noninstitutionalized U.S. population [64] . The geometric means of urine cadmium were 0.28 and 0.40 μ/g in men and women, respectively, in NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) For descriptive purposes, we estimated combined relative risks for stroke and PAD, although the small number of studies and the heterogeneity regarding study design and outcome definition limits the interpretation of these associations across studies. In our meta-analysis we found no association with stroke although only five studies met the inclusion criteria [26, . The association, however, was relatively strong and significant. One study from a Belgium population reported an association of blood, but not urine, cadmium with PAD [70] . The point estimates and associated confidence intervals, however, were not reported and we were thus unable to include this study in our meta-analysis.
Only two studies reported associations with HF (Peters et al. Finally, our search strategy retrieved some occupational studies evaluating clinical CVD endpoints [71] [72] [73] [74] , although they did not meet inclusion criteria because they did not use biomarkers of cadmium exposure and did not account for potential confounding introduced by age, sex or smoking. In most of the studies, cadmium exposure was not associated with CVD [72] [73] [74] . One study from England, however, reported a borderline statistically significant excess of cerebrovascular disease mortality [71] . The healthy worker effect, uncertainties in exposure and outcome assessment, the lack of adjustment for relevant confounders and likely exposures to multiple toxicants, limit the interpretability of those results.
Cadmium and CVD: Differences by Sex
We evaluated pooled associations separately in men and women because women have higher cadmium levels than men and some [25, 27, 58, 62 •, 63•, [75] [76] [77] , but not all [18, 26, 60•, 78] , epidemiologic studies have found differences in health outcomes by sex. Based on data from cadmiumpolluted areas from Japan, where women showed increased mortality and incidence of kidney and bone disease [25, 76, [79] [80] [81] [82] , it has been hypothesized that women are more susceptible to cadmium health effects [77] . Ten articles in our systematic review reported results separately for men and women [27, It is possible that different cardiovascular endpoints show sex differences at different concentrations of exposure, different sources, routes and patterns of cadmium exposure and differential residual confounding for smokers versus nonsmokers. It is also possible that published sex-differences across studies and cardiovascular endpoints are due to random sampling variability. In our meta-analysis, we obtained similar pooled relative risks for men and women supporting that there is no effect modification by sex in cadmium-related cardiovascular effects. Findings of sex differences on cadmiumrelated cardiovascular end-points must be interpreted carefully given the conflicting literature.
Cadmium, Smoking and CVD
Smoking is a major cardiovascular risk factor [83] and an important determinant of cadmium exposure [9, 84] . In the US, indeed, changes in the prevalence of smoking status, cumulative dose, and recent dose have played an important role in the decline of urine cadmium concentrations in the U.S. population, benefiting both smokers and never smokers [84] . In our systematic review, it was important to include adjustment for smoking as inclusion criteria because residual confounding by smoking is a typical concern in epidemiologic studies assessing cadmium-related cardiovascular effects. Smoking status and pack-years are usually defined by selfreport and information on serum cotinine levels (an objective biomarker of recent exposure to tobacco smoke) is rarely available. In three studies [27, 28••, 62 •] that adjusted for pack-years and serum cotinine in addition to smoking status, the associations between cadmium and cardiovascular outcomes remained after adjustment. Nonetheless, positive residual confounding due to misreport of cumulative smoking and smoking status is still possible, among both never and ever smokers.
An additional strategy to evaluate confounding by smoking is to perform separate analyses in never smokers. We estimated combined relative risks from eight studies from the US [ reporting cadmium-related cardiovascular associations in never smokers. Only two studies reported associations of cadmium and CHD in never smokers. Overall, the magnitude of the combined relative risk for cadmium-related CVD in never smokers was similar compared to the overall combined relative risk, but only borderline statistically significant. These findings are consistent with a potential cardiovascular effect of cadmium independent of exposure to tobacco smoke, but need confirmation in larger studies among non-smokers. Among the retrieved papers, seven [27, 28• [52••, 58] of them were statistically significant. The association between cadmium and CVD among never smokers could also be affected by negative confounding, since intake of contaminated vegetables is a major source of cadmium exposure among never smokers [9] . Altogether, there is supportive evidence that cadmium is a cardiovascular risk factor among never smokers, but this evidence is not conclusive. More studies reporting results among never smokers are needed.
Cadmium and CVD Risk Factors
In addition to clinical cardiovascular outcomes, chronic exposure to cadmium has also been associated with CVD risk factors and with subclinical endpoints. Increasing evidence supports that cadmium may play a role in the development of a number of traditional CVD risk factors, including hypertension [16, 63•, 78, 85] and chronic kidney disease [18, 79, 86] , which could mediate in part the cardiovascular effects of cadmium. The association with diabetes is inconsistent across studies [86] [87] [88] . In 195 young women from Austria, cumulative cadmium exposure was associated with increased prevalence of elevated intima media thickness (OR 1.6 [95 % CI: 1.1, 2.3] per standard deviation unit increase in serum cadmium levels) [11] . In 465 women older than 65 years from Sweden, urine cadmium >0.76 μg/g versus <0.18 μg/g was associated with elevated carotid plaque (OR 2. 
Genetic Studies and Cadmium Risk
A novel area of research is the evaluation of genetic loci related to cadmium levels in the human body and cadmium internal dose. For instance, women could be genetically predisposed to have higher long-life cadmium levels for a given level of exposure. The heritability of blood cadmium was 65 % in Swedish non-smoking same-sex female twins compared to only 13 % among non-smoking male twins [90] . In 2,926 adult twins living in Australia, suggestive linkage peaks related to red blood cell cadmium levels were found in chromosomes 2, 18, 20, and X [91] . One polymorphism in the transferrin receptor gene was consistently associated to urine cadmium levels in non smoking women from Argentina (N=172) and Bangladesh (N=359) [92] . In 370 individuals from Thailand, polymorphisms of the glutathione Stransferases were associated to blood cadmium concentrations [93] . In two studies from Turkey, polymorphisms of the MT2A gene was associated to blood [94] and autopsy kidney cadmium levels [95] .
A limited number of studies [96] have evaluated the role of genetic polymorphisms and susceptibility to cadmium health effects. As MTs bind metals and have been associated with protection against cadmium [9] , MTs related polymorphisms could determine susceptibility to cadmium. Indeed, a polymorphism in metallothionein 1A (MT1A) was associated with cadmium-related excretion of urinary beta 2-microglobulin, a marker of cadmium-related renal damage [96] . Polymorphisms in other genes, in addition to MTs, may also modulate cadmium health effects. Co-exposure to other metals could also modify CVD risk in the presence of cadmium, but a systematic evaluation of these factors, including newly developed statistical methods for the evaluation and display of multiple join effects, is needed.
An emerging area of research is the potential mediating role of aberrant DNA methylation, histone modifications and changes in microRNA expression [23] and endocrine disruption pathways [20, 22] in the cardiovascular toxicity of cadmium. High quality experimental and epidemiological studies are needed to evaluate the contribution of cadmium exposure to epigenetic modifications and their potential mediation to CVD development. Correspondingly, appropriate causal inference statistical frameworks for assessing mediation need to be developed. Finally, DNA methylation alterations, which result in changes in gene expression, are mitotically and meiotically heritable [97] . Given that cadmium has been associated with DNA methylation alterations [23] and the fact that reproductive tissues are target organs for cadmium exposure [9] , parental cadmium exposure burden may be heritable across generations. However, in order to evaluate transgenerational effects of cadmium exposure, large-scale family studies with complex pedigrees are needed.
Conclusions
This systematic review and meta-analysis strengthens the evidence in support of chronic cadmium exposure as an independent risk factor for CVD, especially CHD. Given the widespread exposure to cadmium and the few available prospective studies investigating incident outcomes at lower exposure levels, additional prospective studies with long followup, including individual-level exposure assessment and standardized CVD outcomes, and appropriately accounting for confounding by smoking, are needed to establish a causal effect of chronic cadmium exposure on cardiovascular disease. Understanding the role of cadmium in cardiovascular disease at the population level could substantially improve cardiovascular health, as cadmium exposure can be monitored and controlled. In addition to preventive strategies in high-risk patients, which are common in clinical practice, populationbased preventive strategies, such as promoting public and private smoke-free environments, reviewing food safety policies and cadmium safety standards, and limiting cadmium industrial releases into the environment, may reduce cadmium-related cardiovascular disease in the population. sentative of the general US population from 1999-2004 with 8 years of follow-up. After adjusting for sociodemographic and CVD risk factors, including smoking status, recent smoking dose, and cumulative smoking dose increasing cadmium exposure was associated with cardiovascular disease, heart disease and coronary heart disease mortality. This is a large prospective study in American Indian communities from the US with 20 years of follow-up. Cadmium exposure was moderately to strongly associated with incident cardiovascular disease, coronary heart disease, stroke and heart failure. The associations were similar in never smokers. The end-points were ascertained by annual mortality and morbidity reviews of hospitalization and death records and at two research clinic visits. This is the first epidemiologic study evaluating incident cardiovascular outcomes 30.
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